Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Joel Wight; Nada Hamad; Belinda A. Campbell; Matthew Ku; Kenneth Lee; Hannah Rose; Tasman Armytage; Maya Latimer; Hui Peng Lee; Sze Ting Lee; Michael Dickinson; Richard Khor; Emma Verner

doi:10.1111/imj.15533

Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Joel Wight^*, Nada Hamad, Belinda A. Campbell, Matthew Ku, Kenneth Lee, Hannah Rose, Tasman Armytage, Maya Latimer, Hui Peng Lee, Sze Ting Lee, Michael Dickinson, Richard Khor, Emma Verner

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30–40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.

Original language	English
Journal	Internal Medicine Journal
DOIs	https://doi.org/10.1111/imj.15533
Publication status	Published - 2022

Access to Document

10.1111/imj.15533

Cite this

@article{e96a21cd87d94357a76ac4898221169b,

title = "Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance",

abstract = "Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30–40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.",

keywords = "diagnosis, diffuse large B-cell lymphoma, management, prognosis",

author = "Joel Wight and Nada Hamad and Campbell, {Belinda A.} and Matthew Ku and Kenneth Lee and Hannah Rose and Tasman Armytage and Maya Latimer and Lee, {Hui Peng} and Lee, {Sze Ting} and Michael Dickinson and Richard Khor and Emma Verner",

note = "Publisher Copyright: {\textcopyright} 2021 Royal Australasian College of Physicians.",

year = "2022",

doi = "10.1111/imj.15533",

language = "English",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Diffuse large B-cell lymphoma

T2 - a consensus practice statement from the Australasian Lymphoma Alliance

AU - Wight, Joel

AU - Hamad, Nada

AU - Campbell, Belinda A.

AU - Ku, Matthew

AU - Lee, Kenneth

AU - Rose, Hannah

AU - Armytage, Tasman

AU - Latimer, Maya

AU - Lee, Hui Peng

AU - Lee, Sze Ting

AU - Dickinson, Michael

AU - Khor, Richard

AU - Verner, Emma

PY - 2022

Y1 - 2022

N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30–40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.

AB - Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30–40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.

KW - diagnosis

KW - diffuse large B-cell lymphoma

KW - management

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85134505013&partnerID=8YFLogxK

U2 - 10.1111/imj.15533

DO - 10.1111/imj.15533

M3 - Article

SN - 1444-0903

JO - Internal Medicine Journal

JF - Internal Medicine Journal

ER -

Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Abstract

Access to Document

Other files and links

Fingerprint

Cite this